10-Q: Cardiff Oncology Faces Going Concern Doubt Amidst Clinical Progress

Cardiff Oncology reported reduced R&D expenses and promising clinical data for onvansertib, but faces substantial doubt regarding its ability to continue as a going concern.

Summary

• Cardiff Oncology, Inc. filed a Form 10-Q for the quarterly period ended September 30, 2026.
• The company reported a net loss of $8.86 million for the three months ended September 30, 2026, compared to $11.26 million in the prior year period.
• Research and development expenses decreased by $3.2 million to $5.03 million for the three months ended September 30, 2026, compared to the prior year period.
• Selling, general, and administrative expenses increased by $0.5 million to $4.36 million for the three months ended September 30, 2026, compared to the prior year period.
• As of September 30, 2026, the company had $33.8 million in cash, cash equivalents, and short-term investments, which is not sufficient to fund operations for at least the next 12 months.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• The company announced the FDA granted Orphan Drug Designation to onvansertib for CMML and SCLC.
• A Phase 2 trial for onvansertib in RAS-mutated mCRC showed a 72.2% objective response rate with the 30 mg regimen.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the substantial doubt about the company's ability to continue as a going concern and the significant cash burn, despite promising clinical trial data.

Positives

• Promising clinical data for onvansertib in RAS-mutated mCRC, showing a 72.2% objective response rate with the 30 mg regimen.
• FDA granted Orphan Drug Designation to onvansertib for the treatment of CMML and SCLC.
• Research and development expenses decreased by $3.2 million for the three months ended September 30, 2026, indicating cost management.
• The company resolved an intellectual property dispute with Nerviano Medical Sciences S.r.l. (NMS) on September 14, 2026.
• The number of authorized shares of common stock was increased from 150,000,000 to 300,000,000 on October 22, 2026.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient capital resources to fund operations for at least the next 12 months.
• Net loss for the three months ended September 30, 2026, was $8.86 million.
• Cash and cash equivalents and short-term investments totaled $33.8 million as of September 30, 2026, which is insufficient for the next 12 months.
• Selling, general, and administrative expenses increased by $0.5 million for the three months ended September 30, 2026.
• The company may experience additional dilution if it raises additional funds by issuing equity securities.

Risks

• The company's ability to continue as a going concern is dependent on its ability to obtain additional equity or debt financing, obtain government grants, or reduce expenditures.
• There is no certainty that additional funding will be available on acceptable terms, or at all.
• The drug development process is subject to high risks due to uncertainties in clinical testing, regulatory approval, and competition.
• The company may be required to make certain performance-related payments to NMS based on the progress of its Phase 3 trial under the amended license agreement.

Future Outlook

The company expects to continue to incur losses and require additional capital to advance its clinical trial programs. Capital resources are projected to be sufficient to fund operations only to the end of the third quarter of 2027, indicating a need for further financing. The company is preparing for a registrational Phase 3 trial (CRDF-005) for onvansertib in RAS-mutated mCRC.

Management Comments

• Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.
• The Company's ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, obtain government grants or reduce expenditures.
• To the extent that the Company can raise additional funds by issuing equity securities, the Company's stockholders may experience additional dilution.

Industry Context

StockSavvy.ai notes that Cardiff Oncology operates in the highly competitive and capital-intensive clinical-stage biotechnology sector. The company's focus on PLK1 inhibition for various cancers aligns with industry trends of targeted therapies. However, the significant cash burn and the 'going concern' warning are common challenges for companies at this stage, underscoring the critical need for successful clinical development and subsequent funding.

Comparison to Industry Standards

• The objective response rate (ORR) of 72.2% for onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC is significantly higher than typical ORRs for standard of care (SoC) alone in this patient population, which often range from 40-50%.
• The hazard ratio (HR) for progression-free survival (PFS) of 0.55-0.57 in the onvansertib arm suggests a substantial improvement in delaying disease progression compared to SoC, which is a key benchmark in oncology trials.
• The decrease in R&D expenses for the nine months ended September 30, 2026, by $12.5 million, reflects a strategic shift towards later-stage development and potentially lower costs associated with earlier-phase trials, a common practice as companies advance their lead candidates.
• The increase in SG&A expenses, particularly due to legal fees related to the NMS dispute, is a temporary factor that, once resolved, should normalize SG&A spending, aligning with industry expectations for managing legal challenges.

Management Changes

Legal Proceedings

• The intellectual property dispute with Nerviano Medical Sciences S.r.l. (NMS) regarding patent inventorship was resolved on September 14, 2026, through a settlement agreement. The litigation was dismissed with prejudice, and claims were mutually released. Neither party admitted liability or made monetary payments. The license agreement was amended to revise exclusivity, royalty provisions, and milestone payments.

Related Party Transactions

• In the registered direct offering on July 14, 2026, the company sold shares and warrants to certain of its officers and directors (Insiders) at $1.455 per share and warrant. The fair value of these securities exceeded the proceeds allocated to them, resulting in the company recording $0.6 million in stock-based compensation expense.

Stakeholder Impact

• Shareholders may experience dilution if the company needs to raise additional equity financing.
• The 'going concern' status poses a significant risk to all stakeholders, potentially impacting the company's ability to continue operations and the value of their investments.
• Patients awaiting potential treatments like onvansertib are impacted by the company's ability to advance its clinical trials and secure necessary funding.
• Employees' job security is directly linked to the company's financial stability and ability to secure future funding.

Next Steps

• Design and initiate the registrational Phase 3 trial (CRDF-005) for onvansertib in RAS-mutated mCRC.
• Solicit scientific advice from the European Medicines Agency (EMA) on Phase 3 plans.
• Continue manufacturing of clinical material and regulatory activities for the Phase 3 trial.
• Present additional updated data from the Phase 1 CMML trial at the ASH meeting in December 2026.

Key Dates

Recommendation

The company shows promising clinical development for onvansertib, evidenced by strong Phase 2 data and FDA Orphan Drug Designations. However, the significant 'going concern' warning due to insufficient capital is a major red flag. While the recent capital raise and increased authorized shares provide some buffer, the path to profitability and sustained operations remains highly uncertain. A 'hold' recommendation reflects the balance between the potential upside from clinical success and the substantial financial risks.

Keywords

onvansertib, PLK1 inhibitor, RAS-mutated mCRC, clinical-stage biotechnology, Orphan Drug Designation, Phase 3 trial, going concern, cancer treatments